Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
This material is intended for in vitro research use only by qualified professionals
.png)
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg for 4 weeks, then increased in 2.5 mg increments to a target dose of 5-15 mg based on glycemic control and tolerability
For women, especially those over 40 , natural growth hormone levels start to decline, leading to slower metabolism and increased fat storage
Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses
US$ 21.59
US$ 27.01
US$ 26.11
US$ 23.20
